Suppr超能文献

运动神经元病早期的磁共振波谱研究结果。

MR spectroscopy findings in early stages of motor neuron disease.

机构信息

Departments of Neurology, Academic Medical Center, Amsterdam, the Netherlands.

出版信息

AJNR Am J Neuroradiol. 2010 Nov;31(10):1799-806. doi: 10.3174/ajnr.A2217. Epub 2010 Aug 26.

Abstract

BACKGROUND AND PURPOSE

Upper motor neuron degeneration varies in different phenotypes of MND. We used single-voxel MR spectroscopy of the primary motor cortex to detect corticomotoneuron degeneration and glial hyperactivity in different phenotypes of MND with a relatively short disease duration, contributing to further delineation of the phenotypes.

MATERIALS AND METHODS

We prospectively included patients with ALS-B, ALS-L, and PMA and compared their data with those of patients with PLS and healthy controls. Each cohort consisted of 12 individuals. Disease duration was <1 year in ALS and PMA, but longer in PLS by definition. Follow-up examination was at 6 months. We measured ALSFRS-R, finger- and foot-tapping speed, and levels of the following: 1) NAAx, 2) mIns, and 3) Glx in the primary motor cortex.

RESULTS

At baseline, we found significantly decreased NAAx levels and increased mIns levels in PLS. Levels of NAAx and mIns in patients with ALS-L and ALS-B were not significantly different from those in controls, but NAAx levels were significantly lower compared with those in PMA. At follow-up, only in PMA was a decrease of NAAx demonstrated. Glx levels varied widely in all groups. Levels of NAAx and mIns correlated well with clinical variables.

CONCLUSIONS

Metabolite changes suggest neuronal dysfunction and active glial involvement in PLS. The corticomotoneuron is affected in early ALS-B and ALS-L, but at a later stage also in PMA. MR spectroscopy data are useful to obtain insight into the disease process at the level of the upper motor neuron in various phenotypes of MND.

摘要

背景与目的

上运动神经元在不同 MND 表型中存在变性差异。我们使用初级运动皮质的单体素磁共振波谱,对不同 MND 表型(疾病持续时间相对较短)中皮质运动神经元变性和神经胶质活性进行检测,有助于进一步对表型进行描绘。

材料与方法

我们前瞻性纳入 ALS-B、ALS-L 和 PMA 患者,并将其数据与 PLS 患者和健康对照者的数据进行比较。每个队列均包含 12 名个体。ALS 和 PMA 患者的疾病持续时间<1 年,但根据定义,PLS 患者的疾病持续时间更长。随访检查时间为 6 个月。我们测量了 ALSFRS-R、手指敲击速度和足部敲击速度,以及以下物质的水平:1)NAAx,2)mIns 和 3)初级运动皮质中的 Glx。

结果

在基线时,我们发现 PLS 患者的 NAAx 水平显著降低,mIns 水平显著升高。ALS-L 和 ALS-B 患者的 NAAx 和 mIns 水平与对照组相比无显著差异,但与 PMA 患者相比,NAAx 水平显著降低。在随访时,仅在 PMA 患者中观察到 NAAx 水平降低。所有组的 Glx 水平差异较大。NAAx 和 mIns 水平与临床变量密切相关。

结论

代谢物变化提示 PLS 存在神经元功能障碍和活跃的神经胶质参与。在早期 ALS-B 和 ALS-L 中,皮质运动神经元受到影响,但在更晚期,PMA 中也会受到影响。磁共振波谱数据有助于深入了解各种 MND 表型中上运动神经元的疾病进程。

相似文献

1
MR spectroscopy findings in early stages of motor neuron disease.
AJNR Am J Neuroradiol. 2010 Nov;31(10):1799-806. doi: 10.3174/ajnr.A2217. Epub 2010 Aug 26.
2
TDP-43 in differential diagnosis of motor neuron disorders.
Acta Neuropathol. 2007 Jul;114(1):71-9. doi: 10.1007/s00401-007-0234-5. Epub 2007 Jun 14.
3
Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease.
Neuroimage Clin. 2019;24:101984. doi: 10.1016/j.nicl.2019.101984. Epub 2019 Aug 16.
6
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.
Neurology. 2007 Apr 24;68(17):1402-10. doi: 10.1212/01.wnl.0000260065.57832.87.
8
Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia.
Eur J Neurol. 2015 May;22(5):826-31, e57-8. doi: 10.1111/ene.12669. Epub 2015 Feb 12.
9
Cognitive and behavioural changes in PLS and PMA:challenging the concept of restricted phenotypes.
J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):141-147. doi: 10.1136/jnnp-2018-318788. Epub 2018 Aug 3.
10
Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy.
Acta Neuropathol. 2011 Apr;121(4):509-17. doi: 10.1007/s00401-011-0797-z. Epub 2011 Jan 12.

引用本文的文献

1
Primary Lateral Sclerosis: An Overview.
J Clin Med. 2024 Jan 19;13(2):578. doi: 10.3390/jcm13020578.
3
Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging.
Front Neurol. 2021 Aug 16;12:723450. doi: 10.3389/fneur.2021.723450. eCollection 2021.
4
6
Magnetic Resonance Spectroscopy in ALS.
Front Neurol. 2019 May 10;10:482. doi: 10.3389/fneur.2019.00482. eCollection 2019.
7
Neurochemical correlates of functional decline in amyotrophic lateral sclerosis.
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):294-301. doi: 10.1136/jnnp-2018-318795. Epub 2018 Nov 22.
8
Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders.
Curr Neurol Neurosci Rep. 2018 Apr 20;18(6):31. doi: 10.1007/s11910-018-0841-7.
9
Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis.
PLoS One. 2017 May 12;12(5):e0177680. doi: 10.1371/journal.pone.0177680. eCollection 2017.
10
Ultra-High Field Proton MR Spectroscopy in Early-Stage Amyotrophic Lateral Sclerosis.
Neurochem Res. 2017 Jun;42(6):1833-1844. doi: 10.1007/s11064-017-2248-2. Epub 2017 Apr 3.

本文引用的文献

1
Gray matter perfusion correlates with disease severity in ALS.
Neurology. 2010 Mar 9;74(10):821-7. doi: 10.1212/WNL.0b013e3181d3e2dd. Epub 2010 Feb 10.
2
Study of 962 patients indicates progressive muscular atrophy is a form of ALS.
Neurology. 2009 Nov 17;73(20):1686-92. doi: 10.1212/WNL.0b013e3181c1dea3.
3
Epidemiology of ALS in Padova district, Italy, from 1992 to 2005.
Eur J Neurol. 2009 Aug;16(8):920-4. doi: 10.1111/j.1468-1331.2009.02623.x. Epub 2009 Mar 31.
4
Paraplegin mutations in sporadic adult-onset upper motor neuron syndromes.
Neurology. 2008 Nov 4;71(19):1500-5. doi: 10.1212/01.wnl.0000319700.11606.21. Epub 2008 Sep 17.
5
Guidelines for using proton MR spectroscopy in multicenter clinical MS studies.
Neurology. 2007 Nov 13;69(20):1942-52. doi: 10.1212/01.wnl.0000291557.62706.d3.
6
Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study.
J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):33-7. doi: 10.1136/jnnp.2007.118018. Epub 2007 Jun 5.
7
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.
Neurology. 2007 Apr 24;68(17):1402-10. doi: 10.1212/01.wnl.0000260065.57832.87.
8
Disease course and prognostic factors of progressive muscular atrophy.
Arch Neurol. 2007 Apr;64(4):522-8. doi: 10.1001/archneur.64.4.522.
9
Predictability of disease progression in amyotrophic lateral sclerosis.
Muscle Nerve. 2006 Dec;34(6):702-8. doi: 10.1002/mus.20658.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验